Beryl Drugs Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 302214, "name": "Beryl Drugs", "stock_name": "Beryl Drugs", "full_name": "Beryl Drugs Ltd", "name_url": "stocks-analysis/beryl-drugs", "exchange": 0, "exchangecode": "", "primexch": 0, "country_id": 34, "currency": "INR", "cmp": "24.25", "chg": "0.00", "chgp": "0.00%", "dir": 0, "prev_price": "24.25", "mcapval": "12.00 Cr", "mcap": "Micro Cap", "scripcode": 524606, "symbol": "", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 4, "sector_id": 65, "indexname": "India SENSEX", "isin": "INE415H01017", "curr_date": "Jun 10, 03:30 PM", "curr_time": "23:59 PM", "last_traded_at": "Jun 10, 03:30 PM IST", "bse_nse_vol": "6.29 k", "exc_status": "Active", "traded_date": "Jun 10, 2026", "traded_date_str": "2026 06 10", "score": "", "scoreText": "", "Live": 0, "market_time": 0, "is_blur": 1, "is_blur_class": "blur-registerF-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/beryl-drugs-302214-0&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0 } }, "news": { "results": [ { "title": "Beryl Drugs Ltd Valuation Shifts to Very Attractive Amid Mixed Market Returns", "link": "https://www.marketsmojo.com/news/stocks-in-action/beryl-drugs-ltd-valuation-shifts-to-very-attractive-amid-mixed-market-returns-4043133", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/BerylDrugsLtd_valuationdot_4043133.png", "date": "2026-06-10 08:00:32", "description": "Beryl Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, moving from an attractive to a very attractive rating. This change reflects a significant improvement in price metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, positioning the stock as a more compelling option relative to its historical averages and peer group." }, { "title": "Beryl Drugs Gains 5.20%: Strong Quarterly Turnaround Drives Weekly Rally", "link": "https://www.marketsmojo.com/news/stocks-in-action/beryl-drugs-gains-520-strong-quarterly-turnaround-drives-weekly-rally-4024165", "imagepath": "", "date": "2026-05-31 10:01:00", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>25 May:</strong> Stock opens at Rs.19.01, down 4.04% amid broader Sensex gains</p>\n <p><strong>26 May:</strong> Marginal recovery with Rs.19.03 close despite Sensex dip</p>\n <p><strong>27 May:</strong> Sharp 4.31% jump to Rs.19.85 on improving sentiment</p>\n <p><strong>29 May:</strong> Strong quarterly results announced; stock closes at Rs.20.84 (+4.99%)</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.19.81</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">Week Close</d..." }, { "title": "Are Beryl Drugs Ltd latest results good or bad?", "link": "https://www.marketsmojo.com/news/result-analysis/are-beryl-drugs-ltd-latest-results-good-or-bad-4023739", "imagepath": "", "date": "2026-05-30 19:40:24", "description": "Beryl Drugs Ltd's latest financial results for Q4 FY26 indicate a notable shift in performance, with the company returning to profitability after a challenging previous quarter. The reported net profit for the quarter was ₹0.56 crores, a significant improvement from a loss of ₹0.17 crores in the prior quarter. This marks a year-on-year growth of 273.33%, reflecting a recovery in operational performance.\n\nRevenue for Q4 FY26 reached ₹5.13 crores, representing a 29.22% increase compared to ₹3.97 crores in Q4 FY25. This sequential growth of 35.71% from the previous quarter's revenue of ₹3.78 crores highlights a strong recovery trend. Additionally, the operating margin improved to 26.12%, the highest recorded in the last seven quarters, indicating enhanced operational efficiency.\n\nDespite these positive quarterly results, the overall annual performance for FY25 remains concerning, with total revenue declining b..." }, { "title": "Beryl Drugs Q4 FY26: Micro-Cap Pharma Posts Strong Turnaround Amid Margin Recovery", "link": "https://www.marketsmojo.com/news/result-analysis/beryl-drugs-q4-fy26-micro-cap-pharma-posts-strong-turnaround-amid-margin-recovery-4022099", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/BerylDrugs_quaterlyResult_4022099.png", "date": "2026-05-29 11:47:29", "description": "Beryl Drugs Ltd., an Indore-based pharmaceutical manufacturer specialising in intravenous fluids and injectable formulations, reported a remarkable turnaround in Q4 FY26 (January-March 2026), posting net profit of ₹0.56 crores compared to a loss of ₹0.17 crores in the previous quarter. The micro-cap company, with a market capitalisation of just ₹11.00 crores, demonstrated strong sequential momentum with revenue surging 35.71% quarter-on-quarter to ₹5.13 crores, whilst operating margins expanded dramatically to 26.12% from negative territory in Q3 FY26." }, { "title": "Beryl Drugs Ltd Reports Strong Quarterly Turnaround Amid Positive Financial Trend", "link": "https://www.marketsmojo.com/news/stocks-in-action/beryl-drugs-ltd-reports-strong-quarterly-turnaround-amid-positive-financial-trend-4020229", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/BerylDrugsLtd_fintrenddot_4020229.png", "date": "2026-05-29 11:01:05", "description": "Beryl Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has demonstrated a notable financial turnaround in the quarter ended March 2026. The company’s financial trend shifted from flat to positive, with key profitability metrics reaching their highest levels in recent quarters, signalling a potential inflection point for investors amid a challenging market backdrop." }, { "title": "When is the next results date for Beryl Drugs Ltd?", "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-beryl-drugs-ltd-4003788", "imagepath": "", "date": "2026-05-21 23:17:54", "description": "The next results date for Beryl Drugs Ltd is scheduled for 28 May 2026...." }, { "title": "Beryl Drugs Ltd Downgraded to Strong Sell Amid Weak Financials and Bearish Technicals", "link": "https://www.marketsmojo.com/news/stock-recommendation/beryl-drugs-ltd-downgraded-to-strong-sell-amid-weak-financials-and-bearish-technicals-3978899", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/BerylDrugsLtd_mojoScore_3978899.png", "date": "2026-05-07 08:04:16", "description": "Beryl Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Sell to Strong Sell as of 6 May 2026. This revision reflects deteriorating technical indicators, flat financial performance, and weak long-term fundamentals despite some valuation appeal and rising promoter confidence." }, { "title": "Beryl Drugs Ltd Upgraded to Sell on Technical Improvements Despite Flat Financials", "link": "https://www.marketsmojo.com/news/stock-recommendation/beryl-drugs-ltd-upgraded-to-sell-on-technical-improvements-despite-flat-financials-3936551", "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/BerylDrugsLtd_mojoScore_3936551.png", "date": "2026-04-08 08:05:39", "description": "Beryl Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Strong Sell to Sell as of 7 April 2026. This change reflects a nuanced shift in the company’s technical outlook despite ongoing challenges in its financial performance and valuation metrics." } ], "total": 285, "sid": "302214", "stock_news_url": "https://www.marketsmojo.com/news/beryl-drugs-302214" }, "announcements": [ { "caption": "Board Meeting Intimation for CHANGE IN REGISTERED OFFICE OF THE COMPANY", "datetime": "08-Jun-2026", "details": "Beryl Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 16/06/2026 inter alia to consider and approve change in registered office of the company within local limits of the same city", "source": "BSE" }, { "caption": "Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011", "datetime": "08-Jun-2026", "details": "The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Sudhir Sethi", "source": "BSE" }, { "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication", "datetime": "29-May-2026", "details": "NEWSPAPER PUBLICATION OF AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31ST MARCH 2026", "source": "BSE" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "", "data": [ { "title": "BOARD MEETING", "txt": "16 Jun 2026" } ] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "No <strong>Dividend</strong> history available", "data": [] }, { "img": "splits.svg", "title": "SPLITS", "msg": "No <strong>Splits</strong> history available", "data": [] }, { "img": "bonus.svg", "title": "BONUS", "msg": "No <strong>Bonus</strong> history available", "data": [] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

25 May: Stock opens at Rs.19.01, down 4.04% amid broader Sensex gains

26 May: Marginal recovery with Rs.19.03 close despite Sensex dip

27 May: Sharp 4.31% jump to Rs.19.85 on improving sentiment

29 May: Strong quarterly results announced; stock closes at Rs.20.84 (+4.99%)

Week Open

Rs.19.81

Week CloseRead full news article

Are Beryl Drugs Ltd latest results good or bad?

2026-05-30 19:40:24

Beryl Drugs Ltd's latest financial results for Q4 FY26 indicate a notable shift in performance, with the company returning to profitability after a challenging previous quarter. The reported net profit for the quarter was ₹0.56 crores, a significant improvement from a loss of ₹0.17 crores in the prior quarter. This marks a year-on-year growth of 273.33%, reflecting a recovery in operational performance. Revenue for Q4 FY26 reached ₹5.13 crores, representing a 29.22% increase compared to ₹3.97 crores in Q4 FY25. This sequential growth of 35.71% from the previous quarter's revenue of ₹3.78 crores highlights a strong recovery trend. Additionally, the operating margin improved to 26.12%, the highest recorded in the last seven quarters, indicating enhanced operational efficiency. Despite these positive quarterly results, the overall annual performance for FY25 remains concerning, with total revenue declining b...

Read full news article

Beryl Drugs Q4 FY26: Micro-Cap Pharma Posts Strong Turnaround Amid Margin Recovery

2026-05-29 11:47:29

Beryl Drugs Ltd., an Indore-based pharmaceutical manufacturer specialising in intravenous fluids and injectable formulations, reported a remarkable turnaround in Q4 FY26 (January-March 2026), posting net profit of ₹0.56 crores compared to a loss of ₹0.17 crores in the previous quarter. The micro-cap company, with a market capitalisation of just ₹11.00 crores, demonstrated strong sequential momentum with revenue surging 35.71% quarter-on-quarter to ₹5.13 crores, whilst operating margins expanded dramatically to 26.12% from negative territory in Q3 FY26.

Read full news article

Beryl Drugs Ltd Reports Strong Quarterly Turnaround Amid Positive Financial Trend

2026-05-29 11:01:05

Beryl Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has demonstrated a notable financial turnaround in the quarter ended March 2026. The company’s financial trend shifted from flat to positive, with key profitability metrics reaching their highest levels in recent quarters, signalling a potential inflection point for investors amid a challenging market backdrop.

Read full news article

When is the next results date for Beryl Drugs Ltd?

2026-05-21 23:17:54

The next results date for Beryl Drugs Ltd is scheduled for 28 May 2026....

Read full news article

Beryl Drugs Ltd Downgraded to Strong Sell Amid Weak Financials and Bearish Technicals

2026-05-07 08:04:16

Beryl Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Sell to Strong Sell as of 6 May 2026. This revision reflects deteriorating technical indicators, flat financial performance, and weak long-term fundamentals despite some valuation appeal and rising promoter confidence.

Read full news article

Beryl Drugs Ltd Upgraded to Sell on Technical Improvements Despite Flat Financials

2026-04-08 08:05:39

Beryl Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Strong Sell to Sell as of 7 April 2026. This change reflects a nuanced shift in the company’s technical outlook despite ongoing challenges in its financial performance and valuation metrics.

Read full news article